Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

• Status: Active, not recruiting
• Trial end date: 2022-01-31

Summary

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

• Phase: Phase 2

Details

• Lead Sponsor: Canadian Cancer Trials Group
• Collaborator: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Durvalumab; Gemcitabine; Paclitaxel; Tremelimumab